Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Habib Hamidi

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
JAMA Oncology|December 23, 2021
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell CarcinomaRobert J Motzer, Thomas Powles, Michael B Atkins, et al.
Nature Communications|December 3, 2025
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinationsTianshi Lu, Habib Hamidi, Mark A Socinski, et al.
Blood Neoplasia|June 22, 2026
Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trialAdam J Olszewski, Abraham Avigdor, Sunil Babu, et al.
Cancer Cell|November 6, 2020
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis BlockadeRobert J Motzer, Romain Banchereau, Habib Hamidi, et al.
The Journal of Biological Chemistry|December 4, 2014
Estrogen receptor (ER)α-regulated lipocalin 2 expression in adipose tissue links obesity with breast cancer progressionBrian G Drew, Habib Hamidi, Zhenqi Zhou, et al.
Cell Reports. Medicine|November 29, 2025
Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapyYulei Wang, Yinghui Guan, Alexander R Abbas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 3, 2023
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical TrialCharles N Landen, Luciana Molinero, Habib Hamidi, et al.
Human Molecular Genetics|April 11, 2013
Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channelMine S Cicek, Devin C Koestler, Brooke L Fridley, et al.
Cancer Cell|February 17, 2024
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockadeBarzin Y Nabet, Habib Hamidi, Myung Chang Lee, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 20, 2024
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b TrialMarina Y Konopleva, Monique Dail, Naval G Daver, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
JAMA Oncology|December 23, 2021
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell CarcinomaRobert J Motzer, Thomas Powles, Michael B Atkins, et al.
Nature Communications|December 3, 2025
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinationsTianshi Lu, Habib Hamidi, Mark A Socinski, et al.
Blood Neoplasia|June 22, 2026
Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trialAdam J Olszewski, Abraham Avigdor, Sunil Babu, et al.
Cancer Cell|November 6, 2020
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis BlockadeRobert J Motzer, Romain Banchereau, Habib Hamidi, et al.
The Journal of Biological Chemistry|December 4, 2014
Estrogen receptor (ER)α-regulated lipocalin 2 expression in adipose tissue links obesity with breast cancer progressionBrian G Drew, Habib Hamidi, Zhenqi Zhou, et al.
Cell Reports. Medicine|November 29, 2025
Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapyYulei Wang, Yinghui Guan, Alexander R Abbas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 3, 2023
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical TrialCharles N Landen, Luciana Molinero, Habib Hamidi, et al.
Human Molecular Genetics|April 11, 2013
Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channelMine S Cicek, Devin C Koestler, Brooke L Fridley, et al.
Cancer Cell|February 17, 2024
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockadeBarzin Y Nabet, Habib Hamidi, Myung Chang Lee, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 20, 2024
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b TrialMarina Y Konopleva, Monique Dail, Naval G Daver, et al.
Pageof 5